Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06862648 · ClinicalTrials.gov registry record · NA

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

A NA study of Stress Urinary Incontinence (SUI), sponsored by Acoustic Wave Cell Therapy.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
7
Study locations

NCT06862648: Recruiting NA study of Stress Urinary Incontinence (SUI), sponsored by Acoustic Wave Cell Therapy.

NCT06862648 is a NA study of Stress Urinary Incontinence (SUI) that is actively recruiting participants, run by Acoustic Wave Cell Therapy. The registered enrollment target is 130 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06862648, a NA study of Stress Urinary Incontinence (SUI), is actively recruiting participants, sponsored by Acoustic Wave Cell Therapy.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
7
Study locations

Study Summary

The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a blinded, multicenter study. 2. Attend treatment visits during the Treatment Phase, with SUI assessments conducted at specific intervals. 3. Enter a 3-month, treatment-free follow-up phase, with SUI assessment. 4. Proceed to three monthly maintenance treatments, followed by a final SUI assessment at study exit. The total study duration will last approximately 18 months, with each individual's participation lasting approximately 6-8 months. This study aims to provide robust data on the effectiveness, safety, and durability of the SUI-100 device for treating female Stress Urinary Incontinence.

Primary Outcome

The proportion of participants achieving at least a 50% reduction in urine leakage as measured by the average of three 24-Hour Pad Weight Tests (µ-24-PWT).

Interventions

  • DEVICE Acoustic Stimulation Therapy Device
  • DEVICE Sham Acoustic Stimulation Therapy Device

Study Locations (7)

Arizona

  • Arizona Gynecology Consultants - Phoenix

Florida

  • Clinical Research of Central Florida - Winter Haven

Idaho

  • Advanced Specialty Research - Boise

Kansas

  • Cypress Medical Research Center - Wichita

Montana

  • Boeson Research GTF - Great Falls

Nevada

  • Foundation for Female Health Awareness - Las Vegas

Ohio

  • Helios Clinical Research - Middleburg Heights

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-03-25
Est. Completion 2026-11-09
Phase NA
Acoustic Wave Cell Therapy

1 total trials

What NCT06862648 shows while recruiting

NCT06862648 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Stress Urinary Incontinence (SUI) appearing as the primary indexed condition, and to 2 interventions - of which Acoustic Stimulation Therapy Device is the first listed.

NCT06862648 lists 7 locations in 7 states (Arizona, Florida, Idaho).

Frequently Asked Questions

What is clinical trial NCT06862648 about?

NCT06862648 is a clinical study titled "Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence". The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device...

What is the current status of trial NCT06862648?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-03-25. Estimated completion is 2026-11-09.

What conditions does trial NCT06862648 study?

This clinical trial studies the following conditions: Stress Urinary Incontinence (SUI).

What interventions are being tested in trial NCT06862648?

The interventions under investigation include: Acoustic Stimulation Therapy Device (DEVICE), Sham Acoustic Stimulation Therapy Device (DEVICE).

Who is sponsoring clinical trial NCT06862648?

This trial is sponsored by Acoustic Wave Cell Therapy, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06862648 being conducted?

This trial has 7 study locations across Arizona, Florida, Idaho, Kansas, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress Urinary Incontinence (SUI)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06862648's enrollment target sits among peer trials

130 733rd of 2000 higher than 1,257 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06862648, the US trial registry maintained by the National Library of Medicine. NCT06862648 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.